Advertisement

Why has this Alzheimer’s drug not been approved?

A drug designed to slow down cognitive decline in Alzheimer’s, Kisunla, has so far been turned ...

Share this article

12.32 8 Apr 2025


Why has this Alzheimer’s drug not been approved?


Listen to this episode


Share this article

12.32 8 Apr 2025


A drug designed to slow down cognitive decline in Alzheimer’s, Kisunla, has so far been turned down for approval by the EU.

This has led to huge frustration amongst Alzheimer’s experts that hailed the drug as a game-changer.

Joining guest host Anna Daly to discuss is Dr. Laura O’Philbin, Research and Policy Manager at the Alzheimer Society of Ireland, Professor Sean Kennelly, Clinical Director of the Institute of Memory and Cognition in Tallaght University Hospital and listeners who have been personally impacted by the disease.

Image: Eli Lilly


Read more about

Lunchtime Live Highlights

Related Episodes

How much is your personal data...

00:05:29

How much is your personal data worth to tech companies?

The Hard Shoulder

00:05:29


Cabinet signs off on Occupied...

00:10:15

Cabinet signs off on Occupied Territories Bill - should it include services?

The Hard Shoulder

00:10:15


What impact does weather have...

00:05:27

What impact does weather have on working laws?

The Hard Shoulder

00:05:27


Should children avoid slushies...

00:09:36

Should children avoid slushies?

The Hard Shoulder

00:09:36